Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Army Dengue Vaccine Trial Supported by State University of New York

by Global Biodefense Staff
November 28, 2012

The United States Army Medical Research Acquisition Activity (USAMRAA) is awarding a new contract in support of an experimental dengue vaccine trial to the State University of New York, Upstate Medical Center, Syracuse, NY (SUNY). 

SUNY will provide testing services on blood samples collected from human volunteers enrolled in the vaccine trial being executed by the Army’s Medical Research and Material Command and co-development partner GlaxoSmithKline Biologicals (GSK). 

Testing includes the use of a proteomics platform to identify unique protein signatures in volunteers who received various dengue vaccines as early markers of vaccine immunogenicity. Vaccine immunogenicity is a marker of how the vaccine influenced and prepared the recipient’s immune system to prevent infection or disease following natural exposure.

SUNY was cited as having unique subject matter expertise in utilization of proteomics to characterize host immune response in blood samples collected from individuals following acute dengue virus infection or vaccination with a tetravalent live attenuated dengue vaccine. Additionally GSK, the vaccine co-development partner and co-owner of the samples, endorsed SUNY as a preferred collaborator. 

The estimated contract value is $133,000.

Tags: AwardsDengueMosquito-BorneVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC